InvestorNewsBreaks – AnPac Bio-Medical Science (NASDAQ: ANPC) Names New Independent Director

July 23, 2021 14:44:14

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced the appointment of Mr. Chao Feng as an independent director. Mr. Feng, a seasoned executive that has previously worked for two US Fortune 500 Companies in China, will be succeeding Ms. Lin Yu who resigned as a director of the company for personal reasons. Ms. Lin Yu’s resignation and Mr. Feng’s appointment both went into effect as of July 19, 2021. “I welcome Mr. Chao Feng in joining our board of directors. His strong academic background and business management experience, particularly in strategic planning, capital market transactions and sales, will benefit our Company in our pursuit of long-term growth,” AnPac Bio-Medical Science CEO and Chairman of the board of directors Dr. Chris Yu stated in the news release. “Also, on behalf of our management team and board of directors, I would like to thank Ms. Lin Yu for her contributions to the Company.”

To view the full press release, visit

About AnPac Bio

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit the company’s website at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.